Impacts on practice
-
Pharmacists can compound orodispersible films for patients with special needs for whom commercial available products are unsuitable. Thus, the development of orodispersible films as extemporaneous preparations will contribute to personalized medicine.
-
Drug utilization research is an effective tool to explore the most used medications in a patient group. These data can stimulate orodispersible film formulation development.
-
The suitability of an active pharmaceutical ingredient for orodispersibe film formulations strongly depends on its characteristics. Not every active pharmaceutical ingredient is suitable to be formulated into an orodispersible film.
Introduction
Ethics approval
Method
Results
Medications | ATC code | Administration route | % | |
---|---|---|---|---|
1 | Cholecalciferol | A11CC05 | Oral | 61.8 |
2 | Laxative (macrogol/elektrolytes) | A06AD65 | Oral | 52.1 |
3 | Acetaminophen | N02BE01 | Oral | 37.7 |
4 | Acetylsalicylic acid | B01AC06 | Oral | 35.1 |
5 | Esomeprazole | A02BC05 | Oral | 29.4 |
6 | Omeprazole | A02BC01 | Oral | 27.5 |
7 | Furosemide | C03CA01 | Oral | 18.0 |
8 | Emollients and protectivesa | D02AX | Dermal | 15.4 |
9 | Metformin | A10BA02 | Oral | 15.2 |
10 | Simvastatin | C10AA01 | Oral | 13.0 |
11 | Calcium/Vitamin D | A12AX | Oral | 11.8 |
12 | Cranberry | – | Oral | 11.4 |
13 | Metoprolol succinate | C07AB02 | Oral | 11.1 |
14 | Levothyroxine | H03AA01 | Oral | 10.6 |
15 | Hypromellose | S01XA20 | Oculair | 10.0 |
16 | Hydrochlorothiazide | C03AA03 | Oral | 9.7 |
17 | Calcium carbonate | A12AA04 | Oral | 9.7 |
18 | Melatonin | N05CH01 | Oral | 9.5 |
19 | Oxazepam | N05BA04 | Oral | 9.2 |
20 | Enalapril | C09AA02 | Oral | 8.3 |
21 | Lactulose | A06AD11 | Oral | 7.6 |
22 | Fentanyl | N02AB03 | Transdermal | 7.6 |
23 | Oxycodone | N92AA05 | Oral | 7.6 |
24 | Dipyridamole | B01AC07 | Oral | 7.3 |
25 | Temazepam | N05CD07 | Oral | 7.1 |
26 | Citalopram | N06AB04 | Oral | 6.9 |
27 | Ferrofumaraat | B03AA02 | Oral | 6.9 |
28 | Amlodipine | C08CA01 | Oral | 6.6 |
29 | Prednisolone | H02AB06 | Oral | 6.4 |
30 | Insulin Glargine | A10AE04 | Subcutane | 6.2 |
31 | Dermatologicals | b | Dermal | 6.2 |
32 | Zinc product for dermal use | D02AB | Dermal | 5.9 |
33 | Vitamin B12 | B03BA03 | Intramuscular | 5.7 |
34 | Metoprolole tartrate | C07AB02 | Oral | 5.5 |
35 | Haloperidol | N05AD01 | Oral | 5.5 |
36 | Digoxin | C01AA05 | Oral | 5.5 |
37 | Tamsulosin | G04CA02 | Oral | 5.2 |
38 | Alendronic acid | M05BA04 | Oral | 5.0 |
39 | Perindopril | C09AA04 | Oral | 4.7 |
40 | Folic acid | B03BB01 | Oral | 4.5 |
Medications | Patient related characteristics | Manufacturing related characteristics | ||||
---|---|---|---|---|---|---|
ATC-code and name | n* | Indication and uses**, a | Modification of the solid dosage form alloweda | Hazard classb | Taste of the APIc, d | Water solubilityb |
C01BC04 Flecainide (acetaat) | 2 | Irregular heartbeat, 50 mg twice a day | Yes May cause irritation of the mucosa | 3 | – | 48.4 mg/mL at 37 °C |
C01CA17 Midodrine (HCl) | 1 | Orthostatic hypotension, 2.5–10 mg three times daily | Yes | – | – | 7030 mg/L at 25 °C |
C03CA02 Bumetanide | 10 | Heart failure, 0.5–4 mg once a day | Yes | 1 | Slightly bitter | > 20 mg/mL (in base) |
C03DB02 Triamterene | 2 | Hypertension, 25–100 mg daily | Yes | 1 | Slightly bitter | – |
C03EA01 Triamterene/hydrochlorothiazide | 5 | Hypertension, 50/25 mg per day, max 200/100 mg daily | Yes | 3 | Slightly bitter | – |
C07AB03 Atenolol | 9 | Angina pectoris and hypertension, 50–100 mg daily | Yes, May cause irritation of the mucosa | 1 | Bitter | 13,300 mg/L at 25 °C |
C07AB07 Bisoprolol (fumarate) | 18 | Angina pectoris and hypertension, 5 mg once a day | Yes | 1 | Bitter | 2240 mg/L at 25 °C |
C09AA03 Lisinopril (dihydrate) | 9 | Hart failure (and hypertension), 2.5–35 (80) mg daily | Yes May cause irritation of the mucosa | 3 | Neutral | 97 mg/mL at 25 °C |
C09AA04 Perindopril (erbumine) | 21 | Hart failure (and hypertension), 2–4 (8) mg daily | Yes | 2 | – | 1.22 mg/mL |
C09AA05 Ramipril | 5 | Hypertension and cardiovascular prevention, 2.5–10 daily | Yes | 3 | Bitter | 3.5 mg/L |
C09CA06 Candesartan (cilexetil) | 4 | Hart failure and hypertension, 8–32 mg daily | Yes | 3 | Neutral | – |
G04CA01 Alfuzosin (HCl) | 3 | Benign prostate hyperplasia, 2.5–5 mg daily | Yes | 3 | – | 92 mg/L at 25 °C |
G04CB01 Finasteride | 7 | Benign prostate hyperplasia, 5 mg daily | No | 4 | – | 11.7 mg/L |
J01EA01 Trimethoprim | 1 | Prevention of bacterial infections (urinary tract), 100 mg daily | Yes | 3 | Bitter | 400 mg/L at 25 °C |
M01AH05 Etoricoxib | 1 | Pain and inflammation (e.g. rheumatoid arthritis), 60 mg daily | Yes | – | Bitter | 3.28 mg/L |
M03BX01 Baclofen | 8 | Spasticity, 7.5–20 mg 2–4 times per day | Yes | 2 | Bitter | 2090 mg/L |
M03BX02 Tizanidine (HCl) | 5 | Spasticity, 2–4 mg 3–4 times per day | Yes | 1 | Slightly bitter | > 20 mg/mL |
N04BA02 Levodopa/carbidopa | 7 | Parkinson’s disease, 100/25 mg 3 times a day | Yes | 3 | Almost tasteless | 5000 mg/L at 20 °C /3.8 mg/mL |
N04BB01 Amantadine (HCl) | 4 | Parkinson’s disease, 100 mg 1 -2 times a day | No | – | Bitter | 6290 mg/L |
N04BC04 Ropinirole (HCl) | 2 | Parkinson’s disease, 3–24 mg daily | Yes | 2 | – | 133 mg/mL |
N04BC05 Pramipexole (dihydrochloride) | 2 | Parkinson’s disease, 0.088–3.3 daily | Yes | 1 | – | 3900 mg/L at 25 °C |
N04BD01 Selegiline (HCl) | 1 | Parkinson’s disease, 5–10 mg daily | Yes | 1 | – | 18.2 mg/mL |
N05AH02 Clozapine | 5 | Parkinson’s disease or schizophrenia, 25–300 mg daily | Yes | 3 | 11.8 mg/L | |
N05BA01 Diazepam | 2 | Anxiety disorder, 4–80 mg daily | Yes | 3 | First tasteless, bitter aftertaste | 50 mg/L at 25 °C |
N05CD01 Flurazepam (HCl) | 1 | Sleeping disorder, 15–60 mg, usually 30 mg daily | Yes | 1 | Bitter | 500 mg/mL |
N05CD02 Nitrazepam | 1 | Sleeping disorder, 5–10 mg daily | Yes | 2 | Tasteless | > 42.2 mg/mL |
N05CD06 Lormetazepam | 2 | Sleeping disorder, 1–2 mg daily | Yes | 2 | – | – |
N05CD07 Temazepam | 10 | Sleeping disorder, 10–40 daily | Yes | 2 | – | 164 mg/L |
N05CF02 Zolpidem (tartrate) | 2 | Sleeping disorder, 10 mg daily | Yes | 1 | – | 23 mg/mL |
N06AA04 Clomipramine (HCl) | 3 | Depression, 50–750 daily | Yes | 1 | Bitter | 0.293 mg/L at 25 °C |
N06AA09 Amitriptyline (HCl) | 15 | Depression, 50–150 mg daily | Yes | 3 | – | 9.71 mg/L at 24 °C |
N06AB08 Fluvoxamine (maleate) | 4 | Depression, 50–100 mg daily | Yes | 2 | – | – |
N06AX05 Trazodone (HCl) | 2 | Depression, 50–75 mg, 2–3 times a day | Yes | – | Bitter | 27.6 mg/L at 25 °C |
N06AX21 Duloxetine | 1 | Depression, 60–120 mg daily | Capsules may be opened | 3 | – | 13 mg/L at 25 °C |